lack of braf-v600e mutation in stage i and ii of colorectal cancer

نویسندگان

mahsa molaei

royai kishani farahan

mina maftouh

mohammad yaghoob taleghani

چکیده

aim : we aimed to explore the frequency of braf v600e mutation in iranian patients with colorectal cancer (crc) as well as its association with clinic pathological characteristic of patients.   background : crc is the third leading cause of cancer related death. there is a growing body of data showing the association of braf v600e mutation with malignant transformation and clinical outcome of different tumors, including crc. these findings suggest that braf v600e mutation can be used as diagnostic and/or prognostic biomarker for management of cancer patients. patients and methods : a total of 85 patients with sporadic tumor were recruited. braf v600e mutation was investigated using sequencing of extracted dnas from formalin-fixed paraffin-embedded (ffpe) tumor tissues. electropherograms were analyzed using laser-gene 6 software. results : more than 95% of patients were in stage i and ii and none of them were in stage iv. patients were mostly below 55 years old and tumors were dominantly located in the distal colon. of note, no braf v600e mutations were detected in our population. conclusion : our results showed no v600e mutation in the braf gene in stage i and ii of crc patients. further studies in multi-center settings are warranted to examine the prognostic and/or predictive value of this marker in different stages of colorectal cancer patients.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Evaluation of BRAF-V600E gene mutation in colon tissue of patients with colorectal cancer in Iran

Background: Colorectal cancer is one of the most common types of cancer and the cause of death of a large number of patients and requires investigating the causes of the disease and adopting targeted therapies. Considering the diagnostic, therapeutic, and prognostic significance of genetic markers, in the present study BRAF-V600E gene mutation was evaluated in tissue samples of colorectal cance...

متن کامل

Lack of BRAFV600E mutation in stage I and II of colorectal cancer

AIM We aimed to explore the frequency of BRAFV600E mutation in Iranian patients with colorectal cancer (CRC) as well as its association with clinic pathological characteristic of patients. BACKGROUND CRC is the third leading cause of cancer related death. There is a growing body of data showing the association of BRAFV600E mutation with malignant transformation and clinical outcome of differe...

متن کامل

BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer

In stage IV colorectal cancer (CRC), initial resection of the primary tumor is considered to be an important strategy for improving disease outcome. However, there is no consensus on the timing as to when the surgical intervention of the primary tumor should occur. The present study hypothesizes that genetic profiles in CRC may indicate the appropriate treatment strategies for patients with sta...

متن کامل

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.

BACKGROUND Molecular markers in colon cancer are needed for a more accurate classification and personalized treatment. We determined the effects on clinical outcome of the BRAF mutation, microsatellite instability (MSI) and KRAS mutations in stage II and stage III colon carcinoma. PATIENTS AND METHODS Stage II colon carcinoma patients (n = 106) treated with surgery only and 258 stage III pati...

متن کامل

BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.

The serine/threonine-protein kinase B-raf (BRAF) is an oncogene mutated in various neoplasms, including 5-15% of colorectal carcinomas. The T1799A point mutation, responsible for a large majority of these alterations, results in an amino acid substitution (V600E) causing the constitutive activation of a protein kinase cascade. BRAF V600E in MLH1 deficient tumors implicates somatic tumor-only me...

متن کامل

BRAF Mutation in Colorectal Cancer

The BRAF mutant colorectal cancer subgroup is a small population with unique clinicopathological and molecular features. This subgroup has been associated with particularly poor prognosis and advanced disease. The poor response of these patients to available treatments has driven much of the effort in trialling combination targeted treatments involving BRAF and MEK inhibitors. Most recently, an...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
gastroenterology and hepatology from bed to bench

جلد ۹، شماره ۲، صفحات ۲۰۱۶-۹

کلمات کلیدی

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023